依普利酮对高血压能有多大疗效？

How effective is eplerenone in treating high blood pressure? The trial compared the efficacy and safety of eplerenone and losartan in the treatment of hypertension. Methods 80 patients were selected and randomly divided into eplerenone group and losartan group, 40 cases in each group. Eplerenone tablets 50 mg and Losartan potassium tablets 50 mg were given orally once/d for 12 weeks. Before treatment and after the course of treatment, a number of biochemical indicators, 24-hour ambulatory blood pressure, and adverse reactions were recorded. Compared with before treatment, the blood pressure of the two groups dropped significantly, and the differences were statistically significant (P<0.05). Comparing the two groups, there was no significant difference in blood pressure reduction between eplerenone and losartan (P greater than 0.05). Comparing the biochemical indicators between the two groups, the difference was not statistically significant. Conclusion Both eplerenone and losartan, 50 mg once/d, can effectively control blood pressure in patients with mild to moderate hypertension, with good safety and compliance.

Eplerenone is a new type of selective aldosterone receptor blocker that can effectively control hypertension, reduce damage to target organs such as the heart, brain and kidneys, and improve microalbuminuria in patients with type 2 diabetes.

The mechanism of action of eplerenone: it only acts on mineralocorticoid receptors and does not act on androgen and progesterone receptors. Eplerenone treats patients with stage 1 and stage 2 hypertension with similar efficacy rates and reductions in systolic and diastolic blood pressure as enalapril. Eplerenone also has a good antihypertensive effect in patients with essential hypertension with low renin levels for whom angiotensin-converting enzyme inhibitors and angiotensin II receptor inhibitors are not effective. It also has a good antihypertensive effect on simple systolic hypertension, and has a good antihypertensive effect on diet-induced obesity-related hypertension. In addition, eplerenone can significantly reduce the ultrafiltration effect of glomeruli and reduce albuminuria in patients with hypertension. This renal protective effect is more obvious for hypertensive patients with diabetes.